Venetoclax + Dexamethasone + Daratumumab
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AL Amyloidosis
Conditions
AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
Trial Timeline
Jan 8, 2024 → Dec 31, 2028
NCT ID
NCT05486481About Venetoclax + Dexamethasone + Daratumumab
Venetoclax + Dexamethasone + Daratumumab is a phase 1/2 stage product being developed by AbbVie for AL Amyloidosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05486481. Target conditions include AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05486481 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in AL Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZN-d5 | Zentalis Pharmaceuticals | Phase 1/2 | 33 |
| VELCADE | Johnson & Johnson | Phase 1/2 | 41 |
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Carfilzomib + Dexamethasone | Amgen | Phase 1 | 32 |
| Idelalisib | Gilead Sciences | Phase 2 | 51 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Cyclophosphamide + Dexamethasone + Elotuzumab + Lenalidomide | Bristol Myers Squibb | Phase 2 | 51 |
| Isatuximab | Bristol Myers Squibb | Phase 2 | 51 |
| Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab | Sanofi | Phase 1 | 32 |
| Bendamustine Hydrochloride + Isatuximab | Sanofi | Phase 2 | 51 |
| NC-503 (Anti-amyloidotic (AA) Agent) | GSK plc | Phase 2/3 | 64 |
| NTLA-2001 + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| ALN-TTR01 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Patisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |